stockrowGrifols, S.A.
GRFSHealthcare Drug Manufacturers General
Grifols, S.A.’s revenue for fiscal 2025 (year ended December 2025) was $8.5 billion, up 9.07% from fiscal 2024.
- Revenue
- +9.37%
- EPS
- +59.8%
- Free cash flow
- +4.11%
- Total debt
- −6.08%
Quarter to September 2026, against a year earlier
Follow GRFS
Alert me
Grifols, S.A. (GRFS) Gross margin
Grifols, S.A.'s gross margin over the twelve months to 30 September 2026 was 37.6%, down 0.4 percentage points from fiscal 2025 (38.0%). Over the past ten years it has ranged from 34.6% (fiscal 2022) to 49.8% (fiscal 2017); the current reading is higher than 28% of that period. That is below the Drug Manufacturers General industry median of 73.0% and below the Healthcare sector median of 54.5%.
Gross margin, annual
Embed this chart
Annual newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| FY2025 | 38.0% | (0.75) |
| FY2024 | 38.8% | 0.91 |
| FY2023 | 37.8% | 1.04 |
| FY2022 | 36.8% | 2.19 |
| FY2022 | 34.6% | (5.17) |
| FY2021 | 39.8% | 2.99 |
| FY2021 | 36.8% | (5.44) |
| FY2020 | 42.2% | 2.30 |
| FY2020 | 39.9% | (5.99) |
| FY2019 | 45.9% | 2.15 |
Quarterly newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| Sep 2026 | 39.6% | 3.09 |
| Mar 2026 | 36.5% | 1.71 |
| Dec 2025 | 34.8% | (4.57) |
| Sep 2025 | 39.3% | 0.00 |
| 29 more quarters | Free account |
Against its own ten years
Gross margin against peers
| Company | Gross margin |
|---|---|
| NVO Novo Nordisk A/S compare | 80.9% |
| BIIB Biogen Inc. compare | 74.0% |
| SNY Sanofi compare | 73.4% |
| GSK GSK PLC Sponsored ADR compare | 72.6% |
| BMY Bristol Myers Squibb Company compare | 69.2% |
| OGN Organon & Co. compare | 53.1% |
| AMRN Amarin Corporation PLC compare | 40.9% |
| GRFS Grifols, S.A. | 37.6% |
| NSRX Nasus Pharma Ltd. compare | — |
| Drug Manufacturers General industry median | 73.0% |
| Healthcare sector median | 54.5% |
| Market median | 46.0% |
What Gross margin is
Gross Margin tells an investor how much of each sale a company keeps after paying the direct costs of making or buying what it sells.
Gross Profit ÷ Revenue
More on GRFS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement